Orexo AB (publ) (ORXOY)
OTCMKTS · Delayed Price · Currency is USD
2.600
-0.400 (-13.33%)
At close: Dec 17, 2025
Orexo AB Revenue
In the year 2025, Orexo AB had annual revenue of 26.00M SEK, down -95.59%. Orexo AB had revenue of 3.30M in the quarter ending December 31, 2025, a decrease of -97.94%.
Revenue
26.00M SEK
Revenue Growth
-95.59%
P/S Ratio
38.20
Revenue / Employee
250.00K SEK
Employees
104
Market Cap
107.76M USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.00M | -564.00M | -95.59% |
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
Orexo AB News
- 7 weeks ago - Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript - Seeking Alpha
- 4 months ago - Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Orexo AB (ORXOF) Q3 2025 Earnings Call Highlights: Promising R&D Progress Amidst Market ... - GuruFocus
- 4 months ago - Orexo AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 months ago - Q3 2025 Orexo AB Earnings Call Transcript - GuruFocus
- 5 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire
- 9 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 11 months ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire